Research programme: NMDA receptor antagonists - Yaupon Therapeutics

Drug Profile

Research programme: NMDA receptor antagonists - Yaupon Therapeutics

Alternative Names: Analgesics - Yaupon Therapeutics; Norketamine; S-norketamine; YT 1006

Latest Information Update: 12 Jan 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Yaupon Therapeutics
  • Developer Ceptaris Therapeutics
  • Class Cyclohexanes
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Neuropathic pain

Most Recent Events

  • 05 Jan 2012 Discontinued - Preclinical for Neuropathic pain in USA (PO)
  • 02 Feb 2005 YT 1006 is available for licensing (http://www.yaupontherapeutics.com)
  • 03 Nov 2004 Preclinical trials in Neuropathic pain in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top